The Latest Press Release

RENATO CORPORATION MERGES WITH A MAJOR MEDICAL GROUP,

ANNOUNCES NEW BOARD OF DIRECTORS AND COMPANY BUSINESS PLAN

 

 

Miami, Florida--August 4, 2010 – Renato Corporation (DE:4OZ)- is pleased to announce the merger with the a major pharmaceutical group in California and Texas as well as 8 medical clinics in California and Arizona. Due diligence has just completed and we look forward to the closing of the merger within the next 14 days.

 

Healthcare in the United States is undergoing a profound change, driven by both legislation and cost.  The new healthcare legislation, the excessive cost of American Health Care, and an estimated 35 million more people under the healthcare will drive the growth of medical clinic groups.

 

The 8 medical clinics have a combined revenue of $10.5 million dollars.

 

This group operates 20 natural pharmacies in southern California and Texas and has annual revenues in excess of $8 million, targeted primarily at the Hispanic market, the fastest growing segment of the US population, with vitamins, nutraceuticals and wellness products, the fast growing category of consumer consumption..

 

The merger of the health clinics with the natural pharmacies is an ideal mix that is designed to enhance the bottom line of both operations with a blend of Hispanic and Non Hispanic clientele.

 

The established revenues of the properties plus the expected growth of the merged entity will ensure the success of Renato Corporation. The company is in serious discussion with a further 8 groups comprising 27 clinics with revenue in 2010 of approximately $65 million and EBITDA of $14.5 million.

 

The incoming board comprises Bob Pritchard as Chairman as well as Marketing Director with Dwight Staffelback BA, MS Public Administration will take on the position as CEO and John Falting is taking up position as Company Secretary for the group.

 

 As of August 2, 2010, the new Board of Directors of Renato Corporation is re-structuring the company’s corporate business plan and is evaluating all existing negotiations and agreements.

 

www.renatocorp.com      www.renatocorp.de.

 

About Renato Corporation

 

At Renato Corporation it is the company's objective to provide diverse early detection diagnostic technologies utilizing its current experience, reputation and expertise within the international health care industry. Introducing and making available these non-invasive technologies through private health care firms and health and wellness centres in an affordable manner is our immediate focus.

 

The company's mission is to carefully select where these advanced diagnostic technologies will be placed to ensure unparalleled delivery of customer service and satisfaction in the field of non-invasive early detection disease diagnosis and management.

 

Innovative information technology platforms are enabling new models for more efficient, effective and safer healthcare delivery. It is inevitable, that the economic strain on todays health care systems worldwide will realize the ever increasing need for early detection diagnostic devices and services.

 

Disclaimer & Safe Harbor Statement:
This release includes forward looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise. “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995

VANGUARD PHARMACEUTICAL CORPORATION REJECTS RENATO CORPORATION INTEREST OWNERSHIP PROPOSAL

Miami, Fla—October 15, 2009—Renato Corporation (4OZ:DE)- board director Arunas Morkunas confirmed today that Vanguard Pharmaceutical Corporation has rejected the recent proposal from Renato to acquire a 40% interest in the company. “The board of directors of Vanguard believes the offer to be fiscally unsatisfactory”, sited Renato director,  Arunas Morkunas.

At this juncture the board will consider its option of submitting a second proposal to Vanguard or pursuing similar opportunities in these markets.

The company continues to build on its non-invasive medical diagnostic technology operations.

RENATO CORPORATION SUBMITS INVESTMENT PROPOSAL TO ACQUIRE INTEREST IN VANGUARD PHARMACEUTICAL CORPORATION

Miami, Fla—Sept.24, 2009—Renato Corporation (4OZ.F)- has completed it due diligence into Vanguard Pharmaceutical Corporation and has submitted a proposal for a direct investment into the company.  Renato has informed Vanguard that it desires to acquire 40% interest in the company for an undisclosed amount of cash and stock.  Vanguard has 10 business days to consider and respond to the offer.

The company will relay Vanguard’s decision to shareholders after the allotted time period stated.

www.renatocorp.com    www.renatocorp.de 

About Vanguard Pharmaceutical
Latin America is set to emerge as a globally significant market and its generics market is conservatively expected to reach US$6.4 billion by the year-end of 2009. Vanguard has been performing market price analysis of its drugs in several South American countries and has found their prices to be significantly lower than recent generic bid prices.
Vanguard is currently developing and evaluating subsidiary teams in Peru, Colombia, Brazil, and Paraguay who will bid on government tenders and distribute drugs in the private sector. Vanguard has recently travelled to both Peru and Colombia to set up teams in each country.

About Renato Corporation

Renato Corporation has decisively positioned itself to provide advanced diagnostic care via private clinics and health and wellness centers here in North America, and internationally. In addition the company is broadening its business base building generic pharmaceutical facilities in developing countries.

Our professionally staffed clinics will be equipped with the latest non invasive diagnostic devices available to date. Renato Corporation will ensure that non-invasive diagnostic technologies such as Thermography and Electronic Beam Tomography (EBT) body scanning will be accessible to the general public.

At Renato Corporation, it is our pledge to continually seek out the latest innovative advanced medical diagnostic technologies available to continually provide the very best affordable private health care to our clients.

RENATO CORPORATION UTILIZING NATURAL THERMAL IMAGING ENHANCEMENT SUPPLEMENT IN COMPANY’S DIAGNOSTIC CLINICS

Miami, Fla.—August 14,   2009—Renato Corporation (GR:4OZ)—has started  testing a  natural supplement, specifically formulated for Renato,  to improve thermal digital diagnostic imaging test results. The chemical free, natural formulation will be used in select Renato Corporation Diagnostic Clinics.

The company will carefully evaluate the products effectiveness in enhancing digital thermal diagnostic imaging and reducing false positives. The all natural formulation is expected to provide medical diagnostic technicians with intensified advanced thermal imaging accuracy and early detection diagnosis.

Once the company has concluded testing of the product and results are satisfactory, Renato will implement the product usage in all of its clinics. Renato will also consider making the product available to medical diagnostic firms creating additional revenue for the company.

 www.renatocorp.com     www.renatocorp.de 

RENATO CORPORATION EXPANDS ITS MEDICAL DIAGNOSTIC TECHNOLOGY CLINICS TO INTERNATIONAL MARKETS

Miami, Fla—June 4, 2009—Renato Corporation (4OZ:DE) Frankfurt—has introduced its first thermal imaging medical diagnostic clinic into the international market. The corporation, after extensive research and negotiations, has a concentrated objective to make available diagnostic thermal imaging clinics in mature demographic based areas that have become increasingly receptive to early detection health and wellness technology.

Thermography is a noninvasive diagnostic technique that allows the examiner to visualize and quantify changes in skin surface temperature. An infrared scanning device is used to convert infrared radiation emitted from the skin surface into electrical impulses that are visualized in color on a monitor. This visual image graphically maps the body temperature and is referred to as a thermogram. The spectrum of colors indicate an increase or decrease in the amount of infrared radiation being emitted from the body surface.The major clinical value is in its high sensitivity to pathology in the vascular, muscular, neural and skeletal systems and as such can contribute to the pathogenesis and diagnosis made by the clinician.

The clinic, located in Canada is the first of many that Renato intends to introduce to diverse international markets.

Renato Corporation to Enter Into Joint Venture Program With Generic Drug Manufacturer -- Board Ceases Investment Negotiations With Stem Cell Research and Treatment Company Tissu

About Renato Corporation

Forward-Looking Statements

Click Here to See Even More Press Releases @ Yahoo Finance >>